LIWANLI Innovation Co Ltd

TW:3054 Taiwan Drug Manufacturers - Specialty & Generic
Market Cap
$212.80 Million
NT$7.04 Billion TWD
Market Cap Rank
#21286 Global
#1158 in Taiwan
Share Price
NT$87.30
Change (1 day)
+20.91%
52-Week Range
NT$18.75 - NT$87.30
All Time High
NT$87.30
About

LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more

LIWANLI Innovation Co Ltd (3054) - Total Assets

Latest total assets as of June 2025: NT$776.15 Million TWD

Based on the latest financial reports, LIWANLI Innovation Co Ltd (3054) holds total assets worth NT$776.15 Million TWD as of June 2025.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

LIWANLI Innovation Co Ltd - Total Assets Trend (2003–2024)

This chart illustrates how LIWANLI Innovation Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

LIWANLI Innovation Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

LIWANLI Innovation Co Ltd's total assets of NT$776.15 Million consist of 47.8% current assets and 52.2% non-current assets.

Asset Category Amount (TWD) % of Total Assets
Cash & Equivalents NT$0.00 31.3%
Accounts Receivable NT$8.84 Million 1.1%
Inventory NT$27.36 Million 3.5%
Property, Plant & Equipment NT$0.00 0.0%
Intangible Assets NT$0.00 0.0%
Goodwill NT$0.00 0.0%

Asset Composition Trend (2003–2024)

This chart illustrates how LIWANLI Innovation Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: LIWANLI Innovation Co Ltd's current assets represent 47.8% of total assets in 2024, an increase from 0.0% in 2003.
  • Cash Position: Cash and equivalents constituted 31.3% of total assets in 2024, up from 12.1% in 2003.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2003.
  • Asset Diversification: The largest asset category is inventory at 3.5% of total assets.

LIWANLI Innovation Co Ltd Competitors by Total Assets

Key competitors of LIWANLI Innovation Co Ltd based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
USA $67.26 Billion
Kamada
NASDAQ:KMDA
USA $378.79 Million
One World Pharma Inc
OTCQB:OWPC
USA $6.62 Million
Dongwha Pharm.Co.Ltd
KO:000020
Korea ₩654.63 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥27.28 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
China CN¥4.97 Billion
Kotra Industries Bhd
KLSE:0002
Malaysia RM363.90 Million

LIWANLI Innovation Co Ltd - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.04 - 0.50

Lower asset utilization - LIWANLI Innovation Co Ltd generates 0.13x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -15.00% - 5.10%

Negative ROA - LIWANLI Innovation Co Ltd is currently not profitable relative to its asset base.

LIWANLI Innovation Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 13.30 12.75 9.10
Quick Ratio 11.28 11.30 8.35
Cash Ratio 0.00 0.00 0.00
Working Capital NT$346.46 Million NT$ 380.47 Million NT$ 527.49 Million

LIWANLI Innovation Co Ltd - Advanced Valuation Insights

This section examines the relationship between LIWANLI Innovation Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.66
Latest Market Cap to Assets Ratio 0.06
Asset Growth Rate (YoY) -5.0%
Total Assets NT$792.19 Million
Market Capitalization $49.55 Million USD

Valuation Analysis

Below Book Valuation: The market values LIWANLI Innovation Co Ltd's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: LIWANLI Innovation Co Ltd's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for LIWANLI Innovation Co Ltd (2003–2024)

The table below shows the annual total assets of LIWANLI Innovation Co Ltd from 2003 to 2024.

Year Total Assets Change
2024-12-31 NT$792.19 Million -5.03%
2023-12-31 NT$834.17 Million +3.50%
2022-12-31 NT$805.93 Million -14.98%
2021-12-31 NT$947.90 Million -5.53%
2020-12-31 NT$1.00 Billion -11.52%
2019-12-31 NT$1.13 Billion +6.80%
2018-12-31 NT$1.06 Billion -33.87%
2017-12-31 NT$1.61 Billion -7.49%
2016-12-31 NT$1.74 Billion +4.62%
2015-12-31 NT$1.66 Billion -13.42%
2014-12-31 NT$1.92 Billion -10.56%
2013-12-31 NT$2.14 Billion +44.52%
2012-12-31 NT$1.48 Billion +19.98%
2011-12-31 NT$1.24 Billion +20.22%
2010-12-31 NT$1.03 Billion -16.72%
2009-12-31 NT$1.23 Billion +57.96%
2008-12-31 NT$781.16 Million +5.50%
2007-12-31 NT$740.41 Million -0.09%
2006-12-31 NT$741.11 Million +38.95%
2005-12-31 NT$533.37 Million -44.66%
2004-12-31 NT$963.72 Million -22.96%
2003-12-31 NT$1.25 Billion --